Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: A systematic review and meta-analysis

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Liu, Yanqiong ^a   Chen, Jun Qiang ^a   Xie, Li ^a   Wang, Jian ^a   Li, Taijie ^a   He, Yu ^a   Gao, Yong ^b   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin; Incidence; Mortality; NSAID; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; DRUG EFFECT; HUMAN; META ANALYSIS; POPULATION; PROSTATE CANCER; SYSTEMATIC REVIEW; COHORT ANALYSIS; INCIDENCE; MALE; METHODOLOGY; MORTALITY; PROSTATIC NEOPLASMS; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; HUMANS; INCIDENCE; MALE; ODDS RATIO; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK;

EID: 84899137695     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-55     Document Type: Article

References (66)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014, 64:9-29. 10.3322/caac.21208, 24399786.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241. 10.3322/caac.21149, 22700443.
3. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78. 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G, 10579801.
4. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000, 89:589-596. 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C, 10931458.
5. Khor LY, Bae K, Pollack A, Hammond ME, Grignon DJ, Venkatesan VM, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Dicker AP. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007, 8:912-920. 10.1016/S1470-2045(07)70280-2, 2080621, 17881290.
6. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998, 90:1529-1536. 10.1093/jnci/90.20.1529, 9790545.
7. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989, 299:1247-1250. 10.1136/bmj.299.6710.1247, 1838122, 2513898.
8. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5:138-146. 10.1097/00001648-199403000-00003, 8172988.
9. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998, 7:869-873.
10. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998, 77:511-515.
11. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002, 168:1985-1988. 10.1016/S0022-5347(05)64277-2, 12394690.
12. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003, 88:684-688. 10.1038/sj.bjc.6600760, 2376336, 12618874.
13. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88:1687-1692. 10.1038/sj.bjc.6600945, 2377131, 12771981.
14. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005, 97:975-980. 10.1093/jnci/dji173, 15998950.
15. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005, 14:390-396. 10.1158/1055-9965.EPI-04-0532, 15734963.
16. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C. Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006, 15:43-45. 10.1097/01.cej.0000180665.04335.de, 16374228.
17. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006, 17:251-256. 10.1007/s10552-005-0450-z, 16489532.
18. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007, 99:608-615. 10.1093/jnci/djk132, 17440162.
19. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010, 19:3185-3188. 10.1158/1055-9965.EPI-10-0942, 3005534, 20935064.
20. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011, 128:2444-2452. 10.1002/ijc.25811, 3445018, 21128233.
21. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer 2011, 105:452-459. 10.1038/bjc.2011.252, 3172909, 21750557.
22. Kopp TI, Friis S, Christensen J, Tjonneland A, Vogel U. Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men. Cancer Genet 2013, 206:266-278. 10.1016/j.cancergen.2013.06.001, 23880210.
23. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000, 7:169-170.
24. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002, 13:427-434. 10.1023/A:1015788502099, 12146847.
25. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77:219-225. 10.4065/77.3.219, 11888024.
26. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003, 106:409-415. 10.1002/ijc.11250, 12845682.
27. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:649-653.
28. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006, 12:130-135.
29. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 2006, 164:984-989. 10.1093/aje/kwj294, 16931544.
30. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 2006, 15:158-164. 10.1097/01.cej.0000197451.02604.25, 16523013.
31. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007, 42:193-212. 10.1007/1-4020-5688-5_9, 17612052.
32. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010, 172:578-590. 10.1093/aje/kwq175, 2950822, 20688905.
33. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011, 6:e16412. 10.1371/journal.pone.0016412, 3030588, 21297996.
34. Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 2012, 107:207-214. 10.1038/bjc.2012.227, 3389420, 22722313.
35. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320:1642-1646. 10.1136/bmj.320.7250.1642, 27410, 10856067.
36. Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Neal DE, Martin RM. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 2011, 128:1442-1448. 10.1002/ijc.25465, 20506261.
37. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013, 49:938-945. 10.1016/j.ejca.2012.09.030, 23079475.
38. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010, 127:1680-1691. 10.1002/ijc.25186, 20091856.
39. Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol 2014, 25:154-159. 10.1093/annonc/mdt428, 24356627.
40. Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: acohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014, 65:635-641. 10.1016/j.eururo.2013.01.007, 23351721.
41. Cardwell CR, Flahavan EM, Hughes CM, Coleman HG, O'Sullivan JM, Powe DG, Murray LJ. Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control 2013, 24:33-43.
42. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila) 2012, 5:1223-1228. 10.1158/1940-6207.CAPR-12-0171, 3526345, 22961777.
43. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012, 30:3540-3544. 10.1200/JCO.2011.41.0308, 3454771, 22927523.
44. Stock DC, Groome PA, Siemens DR, Rohland SL, Song Z. Effects of non-selective non-steroidal anti-inflammatory drugs on the aggressiveness of prostate cancer. Prostate 2008, 68:1655-1665. 10.1002/pros.20834, 18698582.
45. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004, 24:3177-3184.
46. Lipworth L, Friis S, Blot WJ, McLaughlin JK, Mellemkjaer L, Johnsen SP, Norgaard B, Olsen JH. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther 2004, 11:156-163. 10.1097/00045391-200405000-00002, 15133529.
47. Moher D, Liberati A, Tetzlaff J, Altman DG., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097. 10.1371/journal.pmed.1000097, 2707599, 19621072, PRISMA Group.
48. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009, Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
49. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
51. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998, 280:1690-1691. 10.1001/jama.280.19.1690, 9832001.
52. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
53. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
54. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101. 10.2307/2533446, 7786990.
55. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
56. Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 2000, 1:247-262. 10.1093/biostatistics/1.3.247, 12933507.
57. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012, 131:581-587. 10.1007/s10549-011-1747-0, 21898115.
58. Xu JL, Yin ZQ, Gao W, Liu LX, Wang RS, Huang PW, Yin YM, Liu P, Yu RB, Shu YQ. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 2012, 13:44-51. 10.1016/j.cllc.2011.06.009, 21813335.
59. Liu Y, Lu Y, Wang J, Xie L, Li T, He Y, Peng Q, Qin X, Li S. Association between non-steroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis. Br J Clin Pharmacol 2013, doi:10.1111/bcp.12311.
60. Li S, Liu Y, Zeng Z, Peng Q, Li R, Xie L, Qin X, Zhao J. Association between non-steroidal anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. Cancer Causes Control 2013, 24:1505-1516. 10.1007/s10552-013-0227-8, 23677334.
61. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004, 90:93-99. 10.1038/sj.bjc.6601416, 2395299, 14710213.
62. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006, 55:115-122. 10.1136/gut.2004.047100, 1856377, 16118353.
63. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397-11403. 10.1074/jbc.275.15.11397, 10753955.
64. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001, 58:127-131. 10.1016/S0090-4295(01)01255-9, 11502467.
65. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007, 121:1571-1578. 10.1002/ijc.22788, 2430098, 17450530.
66. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J Cancer Res Clin Oncol 2001, 127:411-417. 10.1007/s004320000225, 11469677.